Top View
- Radiographic Progression in Clinical Trials in Rheumatoid Arthritis: a Systemic Literature Review of Trials Performed by Industry
- Medications Requiring Prior Authorization
- Prolia, INN-Denosumab
- The Effect of Denosumab, the Inhibitor for Receptor
- Circular RNA Circikbkb Promotes Breast Cancer Bone Metastasis
- (Prolia) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023
- Colorado 4Th Tier Medication List
- Precertification, High Dollar Medication Approvals, and Utilizing
- NEW 2018 Specialty Drugs
- Pharmaphacts
- MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional
- Neupogen, Neulasta, Zarxio, Leukine, Granix
- Lumicera Specialty Drug List
- Drugs Requiring Prior Authorization List
- Prior Authorization for Medications
- Denosumab: Recent Update in Postmenopausal Osteoporosis
- METASTATIC RENAL CELL CARCINOMA (Case Study) Disclosures
- Effects of Denosumab in Japanese Patients with Rheumatoid Arthritis
- Osteoclasts and Microgravity
- Impact of Cytokines and T Lymphocytes Upon Osteoclast Differentiation and Function Matthew T Gillespie
- Drug Safety Update
- Mandibular Osteonecrosis in a Patient Receiving Denosumab and Sunitinib
- Colony-Stimulating Factor 1 Potentiates Lung Cancer Bone Metastasis
- Severe Hepatocytotoxicity Linked to Denosumab
- Amgen Safety Net Foundation Offers Replacement Product for Physician-Administered Medications
- New Target for Precision Medicine Treatment of Giant-Cell
- Prospects of JAK Inhibition in the Framework of Bone Loss
- Osteoclast Fusion: Physiological Regulation of Multinucleation Through Heterogeneity— Potential Implications for Drug Sensitivity
- Management of Patients Under Treatment with Monoclonal Antibodies and New Biological Therapies
- Natural Killer Cells Trigger Osteoclastogenesis and Bone Destruction in Arthritis
- Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
- Prolia (Denosumab) Is a Human Igg2 Monoclonal Antibody with Affinity and Specificity for Human RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
- Locally Aggressive Connective Tissue Tumors Mrinal M
- Bisphosphonates (IV) Approved for QOPI Abstraction Non-Nitrogenous
- Multiple Pulmonary Metastases of Giant Cell Tumor of Bone With
- JTE-952 Suppresses Bone Destruction in Collagen-Induced
- Effects of the Anti-RANKL Antibody Denosumab On
- Global Drug Forecast and Market Analysis to 2023
- Combining Immune Checkpoint Inhibitors with Denosumab: a New Era in Repurposing Denosumab in Oncology? Maria V
- RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia
- Specialty Drug List
- Danish Pharmacovigilance Update 2 Status on Eltroxin® Following Change in Excipients
- Clinigen Signs Distribution Agreement with Amgen in Territories Across Africa and Asia
- Medication-Related Osteonecrosis of the Jaw by Concomitant Nivolumab and Denosumab Treatment Gianfilippo Nifosì1*, Lorenzo Nifosì2 and Antonio Fabrizio Nifosì3
- Drug Safety Newsletter Issue 63
- AA IV Request Form
- RESEARCH NEWS Cancer Drug Shows Promise For
- Medical Injection Drug Program Effective 10/03/2011
- Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer
- Drugs for the Management of Osteoporosis
- Bluecross Blueshield AZ
- WHO Pharmaceutical Newsletter 6
- Medicines Management Newsletter
- BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated with High–Neutropenia Risk Chemotherapy
- Position Paper on MRONJ
- Achieving Value in Oncology: a 5000 to 50 Foot View
- Cost Effectiveness of Pegfilgrastim for Reducing Incidence of Febrile
- Request Guidelines Submitting Your Request
- The Osteosarcoma Microenvironment: a Complex but Targetable Ecosystem